Back to search resultsSummaryRMgm-1239
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 25831536 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Sturm A; McFadden GI |
Name Group/Department | Plant Cell Biology Research Centre, School of BioSciences |
Name Institute | University of Melbourne |
City | Melbourne |
Country | Australia |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-1239 |
Principal name | PbATPβKO |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Slightly reduced growth rate of blood stages |
Gametocyte/Gamete | Slightly reduced (but not significant) production of gametocytes |
Fertilization and ookinete | In vitro: Comparable activation of female gametocytes and production of zygotes, and a slight, but significant decrease in ookinete conversion rates for PbATPβKO in comparison with wild type parasites. In vivo (mosquito midgut): The proportion of PbATPβKO activated females was substantially reduced in vivo (under 2%) compared with wild type (40%). Similarly, the PbATPβKO line generated far fewer zygotes (0%) and ookinetes (0%) in vivo. Failure to activate, generate zygotes, and mature to ookinetes by the PbATPβKO female gametocytes in vivo was also evident in the preponderance of aberrant females in vivo (90%) compared with in vitro (1%). No ookinetes were observed at 22 h. |
Oocyst | No formation of oocysts |
Sporozoite | No formation of oocysts; no formation of sporozoites |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation In vitro: Comparable activation of female gametocytes and production of zygotes, and a slight, but significant decrease in ookinete conversion rates for PbATPβKO in comparison with wild type parasites. PbATPβKO in vitro ookinetes were artificially fed to mosquitoes, and, after 12 d, midguts were checked for oocysts. In 50 mosquitoes from four independent feeds, no oocysts were found. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1450300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1235700 | ||||||||||||||||||||||||
Gene product | ATP synthase subunit beta, mitochondrial | ||||||||||||||||||||||||
Gene product: Alternative name | PbATPβ protein | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | To disrupt the ATP synthase, β subunit gene, a replacement plasmid was created using the vector pL0006 (MR4), which contains the resistance marker gene encoding for human dihydrofolate reductase (hDHFR). The 5′ and 3′ integration sequences for homologous recombination were amplified by PCR using primer combinations 27/29 (5′ integration sequence, 0.87 kb) and 30/31 (3′ integration sequence, 0.51kb). | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |